Teleflex Receives FDA Clearance for the Arrow® Midline with Chlorag+ard® Technology
October 17 2016 - 6:45AM
Business Wire
Teleflex Incorporated (NYSE:TFX), a leading global provider of
medical devices for critical care and surgery, has announced it has
received FDA 510(k) clearance to market its Arrow® Midline with
Chlorag+ard® Technology.
Arrow® Midline with Chlorag+ard® Technology is an
antithrombogenic1 and antimicrobial2 peripheral venous catheter
designed to minimize common midline catheter complications such as
catheter intraluminal occlusion, thrombus accumulation and
microbial colonization on the catheter surface for a minimum of 30
days.1,2,3 Additionally, the new midline is also designed for use
with high-pressure injection for diagnostic studies. The Arrow®
Midline with Chlorag+ard® Technology will enable caregivers to
effectively and economically protect the catheter from potential
costly complications.
“Clinicians are faced with a multitude of vascular access
challenges. Development of new technology to ensure the patient
receives the safest, most effective IV therapy possible should
drive all medical device manufacturers. We at Teleflex continue to
promote the message of ‘The Right Line for the Right Patient at the
Right Time™.’ and through this belief we continue to develop
products that help clinicians to champion better care,” said Jay
White, president and general manager of the Vascular Access
Division of Teleflex. “The Arrow® Midline with Chlorag+ard®
Technology continues to build upon this belief.”
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Chlorag+ard, Deknatel,
Hudson RCI, LMA, Pilling, Right Line, Right Patient, Right Time,
Rusch and Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates.© 2016 Teleflex Incorporated. All
rights reserved. MC-002488
References:
1.
Data on file. AS compared to uncoated
catheters, intravascular ovine model inoculated with Staph aureus.
No correlation between in vitro / in vivo testing methods and
clinical outcomes have currently been ascertained.
2.
In vitro data on file 2010. No correlation
between in vitro / in vivo testing methods and clinical outcomes
have currently been ascertained.
3.
Occlusion - As compared to uncoated PICCs,
in vitro model measuring flush pressure post exposure to human
blood. No correlation between in vitro / in vivo testing methods
and clinical outcomes have currently been ascertained.
Rx only
Contraindication:The Arrow® PICC with Chlorag+ard® Technology is
contraindicated for patients with known hypersensitivity to
chlorhexidine
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017005029/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024